Kateeva (formerly TJet Technologies) is driving new advances in OLED production technology. Our inkjet printing manufacturing equipment solution enables flexible and large-size OLEDs to be produced over large areas and in high volume – with longer lifetimes, higher yields and lower production costs. It’s the first economically viable and production-worthy technique to use printing for low-cost mass-production of OLEDs – which means big innovation for the display industry. And for consumer electronics fans, it means those spectacular 55” OLED TVs will soon be within reach, and cool paper-thin, ultra-light wearable computing products will dazzle with extra smarts and smaller form factors. At our LinkedIn home, we’ll keep you up-to-the-minute on our tech milestones and latest moves. And since we’re huge fans on all-things OLED, we’ll occasionally add other cool technology stuff that inspires us to out-invent – even ourselves!

Shiseido Co., Ltd. engages in the production and sale of cosmetics for men and women. It operates through the following segments: Japan, China, Asia Pacific, Americas, Europe, Travel Retail, Professional, and Others. The Japan, China, Asia Pacific, Americas, and Europe segments sell cosmetics, fragrance, and personal care products with core brands such as Shiseido, clé de peau BEAUTÉ, ELIXIR, MAQUILLAGE, AUPRES, urara, TSUBAKI, Za, and narciso rodriguez in each corresponding region. The Travel Retail segment retails Shiseido, clé de peau BEAUTÉ, bareMinerals, and NARS brands in airport duty-free shops excluding Japan. The Professional segment manages the sale of beauty products in Japan, China, and Asia. The Others segment includes headquarter functions, production, frontier science, and restaurant businesses. The company was founded by Arinobu Fukuhara on September 17, 1872 and is headquartered in Tokyo, Japan.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Nippo Co., Ltd. provides instruction manuals for drugs and medical equipment. The company was founded on September 2, 1946 and is headquartered in Toyama, Japan.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

KBIC offers a platform of networking for about businesses and institutes in their pursuit of innovative collaboration and groundbreaking discoveries in a wide spectrum of medical, pharmaceutical, and biological fields, including the medical device and regenerative medical fields. KBIC’s foremost mission is to enhance human health and vitalize the global healthcare industry through collaborative ties between and among those in the business, academic, governmental and healthcare sectors.

Psychogenics, Inc. specializes in preclinical neurobiology solutions. It offers animal models, behavioral tests, histology/immunohistochemistry, microdialysis/bioanalysis, electrophysiology, molecular biology and pharmacology. The company was founded by Eric Nestler, Benjamin S. Bunney and Daniel Goodman and is headquartered in Paramus, NJ.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Henan Gaoyuan Highway Maintenance Equipment Co., Ltd., established on 2004-04-27, Business scope includes general items:Construction machinery manufacturing;Mechanical equipment research and development;Sales of construction machinery;Auto New Car Sales;Machinery sales;Machinery and Equipment Leasing;Non-residential real estate leases;Auto Parts Wholesale;Auto Parts Retail;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Road Motor Vehicle Production;Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Astellas Pharma Inc. is a Japan-based pharmaceutical company that operates its business in more than 70 countries around the world. It has approximately 16,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. In its FY2019 financial results, revenue achieved about 1,300 billion yen (ca.$12 billion*), and R&D expenses were about 220 billion yen (ca.$1.9 billion*). Astellas' competitiveness comes from its own innovativeness in R&D and extensive network featuring cutting-edge technology garnered through proactive collaborations with academia, bio-ventures, and pharmaceutical companies worldwide. Its R&D activities are managed and promoted by functional centers in the U.S., Japan, and Asia, which enhance agility and efficiency of projects through parallel developments globally. Astellas established the “Focus Area Approach” as its R&D strategy. This approach focuses on building sustainable and expandable drug discovery by selecting the best combination of biology, modality/technology, and disease. The company has identified four prioritized research areas, Blindness & Regeneration, Mitochondria Biology, Genetic Regulation, Immuno-Oncology, named “Primary Focus” where it focuses its resource to strategically expand its pipeline. One of the Astellas’ key focuses that support the strategy is collaborations with academic labs and various pharmaceutical companies, including start-ups. Dedicated teams have been assigned to maximize the value of respective collaborations. These include Astellas Innovation Management, which promotes intaking early-stage innovations, Business Development, which identifies opportunities for inward/outward transactions and executes deals and manages subsequent alliances, and Astellas Venture Management, a corporate venture capital that makes private equity investments in early-stage biotech start-ups in an attempt to potentially reinforce Astellas’ pipeline. In drug discovery activities, the R&D pipeline programs have been reinforced by incorporating external cutting-edge science. In recent years in particular, advanced technologies in areas such as cell therapy and genetic regulation have been added to Astellas’ capabilities. Astellas has also been successful in M&As, including Audentes Therapeutics, Xyphos Biosciences, Nanna Therapeutics, Universal Cells, Ocata Therapeutics, and Mitobridge for unique scientific features. Astellas has demonstrated a strong footprint in late-stage clinical trials and commercialization of its strategic products. In the past three years, it successfully launched three new products (XOSPATA, Evrenzo and PADCEV) and expanded indications of XTANDI worldwide by realizing excellent management of each clinical trial program. Astellas also achieved annual sales of 754.5 billion yen (ca.$6.9 billion*) with XTANDI, Betanis / Myrbetriq / BETMIGA, and Prograf in FY2019 with a strong focus on delivering value through improving patient access and outcomes in the associated therapy areas. Another remarkable approach that Astellas is taking is creating new healthcare solutions beyond medicine based on the existing expertise and knowledge in its Rx business, combined with adjacent technologies from partners. Astellas values research outcomes from all partners and is willing to realize untapped value thereof by collaborating with a partner and maximizing the value of assets by using Astellas’ capability (e.g., funding, facilities, human resources, and know-how). Openness and flexibility in designing alliance mechanisms (e.g. tailored joint study programs and financial arrangements) will help the parties to realize executing a deal in a timely manner. Astellas is committed to creating medical solutions in order to turn innovative science into value for patients and incorporating capabilities of partners. *The exchange rate for the yen, 1USD: 109yen

OG Giken Co., Ltd. is a Japanese private company located in Okayama that manufactures and distributes orthopedic equipment.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Anhui Provincial Hospital, a subsidiary of Province of Anhui, is a Chinese company located in Hefei. The firm provides health related services.

Chongqing Xizhi Machinery Equipment Co., Ltd., established on 2011-05-16, Business scope includes mechanical equipment research and development,design,processing,Sales***[Operations that are prohibited by laws and regulations within the above scope shall not be operated,Laws and regulations stipulate that approval should be obtained, but no business operation is allowed without approval]

Sun Medical Technology Research Corp., part of Misuzu & Sun Medical Holdings Co., Ltd., is a company headquartered in Suwa, Japan. The firm manufactures and distributes blood pumps.

Guangdong Taiantang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines; the planting, processing and sale of Chinese herbal medicines; and the pharmaceutical e-commerce business. Its products include creams, ointments, tablets, capsules, pills, and other medicines. The company was founded in 1995 and is headquartered in Shantou, China.

Provides drug research, development and commercialization services